Kolexia
Laharie David
Gastro-entérologie
Hôpital Haut-lévêque
Pessac, France
493 Activités
447 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Maladie de Crohn Maladies inflammatoires intestinales Rectocolite hémorragique Colite Nécrose Ulcère Sténose pathologique Fistule Rectocolite

Industries

Abbvie
79 collaboration(s)
Dernière en 2023
Janssen
76 collaboration(s)
Dernière en 2023
Edimark
31 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
31 collaboration(s)
Dernière en 2023

Dernières activités

LUCENT-URGE: A Multicenter, Phase 3b, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab
Essai Clinique (Lilly)   07 mars 2024
Anastomose Kono-S : enfin un essai randomisé et contrôlé !
Edimark   23 février 2024
VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment Target
Essai Clinique (Takeda Pharmaceutical)   20 février 2024
Pragmatic trial design to compare real-world effectiveness of different treatments for inflammatory bowel diseases: the PRACTICE-IBD European consensus.
Journal of Crohn's & colitis   17 février 2024
Acute severe ulcerative colitis management: unanswered questions and latest insights.
The lancet. Gastroenterology & hepatology   14 février 2024
Letter: Should ulcerative colitis be monitored more or less invasively?
Alimentary pharmacology & therapeutics   14 février 2024
TRENCH 1: TRansmural hEaliNg Definition in CroHn's Disease - The TRENCH1 Study
Essai Clinique (Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives)   15 janvier 2024
Douleurs chroniques chez les malades en rémission
Edimark   19 décembre 2023
ABTECT - Maintenance: A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Long-term Efficacy and Safety of ABX464 25 mg or 50 mg Once Daily as a Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
Essai Clinique (Abivax S.A.)   15 décembre 2023
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ABX464 Once Daily for Induction Treatment in Subjects With Moderately to Severely Active Ulcerative Colitis
Essai Clinique (Abivax S.A.)   15 décembre 2023